 Enzo Biochem, Inc. ENZ a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,626,170 entitled Sulfonated Sclerostin, Antibodies, Epitopes and Methods for Identification and Use Therefor. The patent is directed to methods for producing monoclonal antibodies against specific regions of human Sclerostin, a protein that is a negative regulator of bone growth. Inhibition of Sclerostin using monoclonal antibodies can be used to promote bone growth for the treatment of osteoporosis. 